
Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...





